Objective To explore the clinical outcomes of rosuvastatin in patients with acute myocardial in-farction complicated with atrial fibrillation.Methods One hundred and sixty-two patients with acute myocardial infarction complicated with atrial fibrillation were randomly divided into 3 groups and treated with different doses of rosuvastatin and conventional treatment,respectively.Comparing the statistical differences between the groups before and after the treatment of cardiac function,blood lipids,and inflammation.Results After treatment,there were statistically significant differences in LVEF,LVESD,LVEDD,FS,TG,TC,HDL-C,hsCRP,TNF-α,IL-6 and LADd in the three groups.Compared with the control group and the low-dose group,the middle-dose group had significant differences in heart function indexes,blood lipids TG,TC,HDL-C indexes,and inflammation in-dexes.With time going by,the heart function indexes and blood lipids indicators(TG,TC,HDL-C)and all indi-cators of inflammation have significant changes.In the three groups of patients,blood TG,TC,HDL-C and in-flammation indexes were significantly decreased with time.The efficacy of the middle-dose group was significantly better than that of the low-dose group and the control group,and the effective rate was higher than that of the low-dose group and the control group.The relapse rate of the middle-dose group was significantly lower than that of the low-dose group and the control group.Conclusion Rosuvastatin can reduce the recurrence rate of atrial fi-brillation in patients with acute myocardial infarction,change the patient's heart function index,blood lipid index and inflammation index effectively.%目的 探究瑞舒伐他汀对急性心肌梗死合并心房颤动(AF)患者临床预后.方法 根据入院先后顺序将162例急性心肌梗死合并AF患者均分为3组,分别进行不同剂量瑞舒伐他汀和常规处理.比较各组患者心功能指标、血脂指标、炎症指标治疗前后的差异.结果 治疗后比较,3组患者左室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、左室短轴缩短率(FS)、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、超敏C反应蛋白(hsCRP)、肿瘤坏死因子(TNF)-α、白细胞介素(IL)-6指标的差异具有统计学意义(P<0.05);中剂量组与对照组、小剂量组比较心功能指标、血脂TG、TC、HDL-C指标、炎症各项指标差异有统计学意义(P<0.05),且随着时间迁移心功能各项指标、血脂 TG、TC、HDL-C指标、炎症各项指标均有显著变化,3组患者随着时间迁移血脂TG、TC、HDL-C指标、炎症各项指标均显著下降.3组患者临床疗效比较,中剂量组疗效显著优于小剂量组和对照组,且有效率高于小剂量组和对照组,中剂量组AF复发率显著低于小剂量组和对照组(P<0.05).结论 瑞舒伐他汀可减少急性心肌梗死合并AF复发率,有效地改患者心功能指标、血脂指标、炎症指标.
展开▼
